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Abstract
Background The prevalence of malignancies after pediatric solid organ transplantation was evaluated in a nationwide study.
Methods All patients who had undergone kidney, liver, or heart transplantation during childhood between the years 1982 and
2015 in Finland were identified. The inclusion criteria were age under 16 years at transplantation and age over 18 years at the last
follow-up day. A total of 233 (137 kidney, 53 liver, and 43 heart) transplant recipients were enrolled. Controls (n = 1157) matched
by the year of birth, gender, and hometown were identified using the Population Register Center registry. The cancer diagnoses
were searched using the Finnish Cancer Registry.
Results Altogether 26 individuals diagnosed with cancer were found, including 18 transplant recipients. Cancer was diagnosed at
a median of 12.0 (IQR 7.8–17.8) years after the transplantation. The transplant recipients’ risk for cancer was significantly higher
when compared with the controls (HR 14.7; 95% CI 6.4–33.9). There was no difference for different graft types. Sixty-one
percent of cancers among the transplant recipients were diagnosed at age older than 18 years.
Conclusion The risk for cancer is significantly higher among young adults having undergone solid organ transplantation during
childhood in comparison with population controls. Careful follow-up and attention to prevent cancers throughout adulthood are
warranted.
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Introduction
Solid organ transplantation is the only curative treatment for
end-state organ failure. Successful pediatric kidney (KTx),
liver (LTx), and heart (HTx) transplantations have been per-
formed for more than three decades, and a new patient group,
long-term survivors after pediatric solid organ transplantation,
has emerged. The knowledge about late complications as well
as morbidity and mortality after solid organ transplantation
has increased in recent years. The most common long-term
complications are related to cardiovascular disease, infections,
and malignancies [1–5].
The risk for cancer is significantly increased in all trans-
plant recipients, and especially among patients with a history
of pediatric solid organ transplantation [6–10]. The incidence
of de novo malignancies among solid organ recipients varies
between 2 and 23%, depending on study population [6–8,
10–13], and the risk for different cancers has been reported
to be as much as 30-fold higher than in the non-transplant
population [10]. The increased prevalence of cancers is related
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to exposure to immunosuppressive medication and oncogenic
viruses [14, 15].
The most common cancer after pediatric solid organ trans-
plantation is post-transplant lymphoproliferative disorder
(PTLD), which altogether covers 52–80% of all cancers after
solid organ transplantation [6, 7, 10–12, 16]. According to the
2016 WHO update, PTLD was classified as lymphoid neo-
plasms into six categories: plasmacytic hyperplasia, infectious
mononucleosis, florid follicular hyperplasia, and polymor-
phic, monomorphic, and classical Hodgkin lymphoma [17].
Previous studies have shown that the incidence of PTLD is
highest after intestinal, liver, heart, and lung transplantation [6,
7]. In addition to the level of immunosuppression, young age
at transplantation and Epstein-Barr virus (EBV) seronegativi-
ty are risk factors for PTLD [7, 8].
It has also been shown that PTLD appears earlier after
transplantation when compared with other malignancies [8].
Kitchlu et al. [10] reported recently that 23% of all deaths
among transplant recipients were caused by malignancies
and that the majority of cancers (68%) leading to death were
PTLDs. In the study by Serrano et al. [18] among pediatric
KTx recipients, 64% of deaths were caused by cancer. A re-
cent report from the USA showed that transplant recipients
had an increased risk for cancer mortality even in comparison
with other cancer patients [19].
In most of the previous studies, the follow-up time was
relatively short and the data on cancer morbidity and mortality
in adulthood after pediatric transplantation are scarce. The
goal of this national registry-based study was to evaluate the
cumulative cancer incidence and cancer-associated long-term
mortality in young adults with a history of kidney, liver, or
heart transplantation during childhood compared with date of
birth, gender, and area of residence-matched controls who
were identified for each transplant case from the Finnish
Population Register Center. We hypothesized that the cumu-




The Ethics Committee of Helsinki University Hospital, the
Institute for National Health and Welfare, and the Office of
the Data Protection Ombudsman approved the study protocol.
Study population
All pediatric solid organ transplantations in Finland have been
performed at the Helsinki University Hospital since 1982. We
identified all the pediatric kidney, liver, and heart transplant
recipients transplanted between January 1, 1982 and
December 31, 2015. The inclusion criteria for the study were
age under 16 years at transplantation and age over 18 years at
the last follow-up day, December 31, 2015. Those transplant
recipients whose age at the last follow-up day would have
been over 18 years but who had died were included in the
study population. Patients with a cancer diagnosis before
transplantation (n = 13) were excluded from the analyses.
A total of 233 (137 kidney, 53 liver, and 43 heart) trans-
plant recipients were included in the study, and each transplant
recipient had 3–5 years of birth-, gender-, and hometown-
matched controls. Hometown matching was based on resi-
dence at moment of transplantation. Totally 1157 controls
were identified using the Population Register Center registry.
The presence of chronic diseases was evaluated from the
Specially Reimbursement Drug Registry. Nine controls had
connective tissue disease, mainly rheumatoid arthritis, and
ten controls had colitis ulcerosa. One of these control subjects
had cancer. One control had kidney transplant during adult-
hood and was excluded from the study population. By linkage
to the Finnish Cancer Registry, all cancer diagnoses among
the transplant recipients and the control subjects diagnosed
between 1982 and 2015 were searched. The coverage of the
Finnish Cancer Registry is 100%, because in Finland, it is
obligatory by the law to report all diagnosed cancers to the
registry. Classification of disease for oncology (ICD-O-3) was
used to categorize the diagnoses [20]. We also reviewed the
medical records of all the patients with reported cancer in
order to verify the accuracy of the registry data as well as to
obtain information about the immunosuppressive medication
and EBV status at the time of cancer diagnosis.
Immunosuppression protocol
Anti-thymocyte globulin (ATG) has been used as induction
therapy in HTx patients from the beginning of our transplant
program. Until the year 2000, kidney and liver recipients did
not receive either monoclonal or polyclonal antibodies as in-
duction therapy. Since the year 2000, basiliximab has been
used as induction therapy in kidney and liver recipients. The
maintenance immunosuppression protocol of the transplant
recipients consisted of triple medication. The most commonly
used drug combination after KTx and LTxwas cyclosporine A
(CsA), azathioprine (AZA), and methylprednisolone. In HTx
recipients, a combination of CsA and AZA was used as pri-
mary immunosuppression until around the year 2010, after
which tacrolimus with AZA or mycophenolic acid (MPA)
has been the f i r s t - cho i ce immunosupp re s s ion .
Methylprednisolone was initially dosed daily and later
switched to alternate-day dosing at 3–6 months after
transplantation.
All the transplant recipients visit our institution at least
annually. These follow-up visits include e.g., evaluation of
graft function, chest X-ray in HTx recipients, abdominal
Pediatr Nephrol
ultrasonography in KTx and LTx recipients, and screening for
EBV nucleic acid testing.
Statistical analyses
SPSS statistics 24 (SPSS Inc., Chicago, IL, USA) and R ver-
sion 3.4.4 were used for data analyses. Data between two
subject groups were compared using Kruskal-Wallis test and
Mann-Whitney U test for continuous variables, and Pearson
chi-squared test and Fisher’s exact test for categorical vari-
ables. The reported survival analyses were carried out with
Cox proportional-hazards models and the PH assumption
was evaluated with Schoenfeld residuals. Cumulative inci-
dence plots and forest plots were used as visualization aids.
A p value less than 0.05 was considered statistically signifi-
cant and all tests were two-tailed. No corrections for multiple
testing were used. Cumulative survival was evaluated with




The descriptive characteristics of the study subjects are shown
in Table 1. The primary causes for kidney transplantation in-
cluded congenital nephrotic syndrome of the Finnish type
(34%), congenital anomalies of kidneys or urinary tract
(23%), cystic diseases (18%), glomerulonephritis (13%), and
miscellaneous (12%) diagnoses; for liver transplantation: bil-
iary atresia (42%), metabolic diseases (30%), acute liver fail-
ure (15%), and miscellaneous (13%); and for heart transplan-
tation: congenital heart defect (49%) and cardiomyopathies
(51%). The median age of all the transplant recipients at the
time of the study was 24.6 (range 0.8–44.0) years and for
those alive at the last follow-up day 25.8 (18.3–44.0) years.
The median follow-up time of all the recipients was 18.0 (0.3–
30.0) years. In total, sixteen kidney and ten liver transplant
recipients received a re-transplant. The mortality rate was
25.8% among the transplant recipients and 0.2% among the
controls (p < 0.001).
Malignancies
Altogether 26 cancers were found: 18 in the transplant recip-
ient group and eight among the controls (Table 2). The trans-
plant recipients’ HR for cancer diagnosis was 15-fold higher
than the controls’ (95%CI 6.4–33.9) (Fig. 1)—additional data
are given in Online Resource (ESM_1). The cumulative can-
cer incidence was 0.95% during the first 5 years post-
transplantation after which it gradually increased up to
12.11% during the follow-up period (up to 25 years)
(Fig. 2). At the time of cancer diagnosis, the transplant recip-
ients were nearly 10 years younger when compared with the
controls (median 18.7 IQR 14.1–22.8 vs. 26.2 IQR 17.2–
28.6 years); however, the difference was not statistically sig-
nificant (p = 0.129).
In the transplant group, all tumors were cancers, whereas in
the control group, one tumor was classified as borderline ma-
lignant tumor (mucinous cystic tumor in the ovary (Table 2).
PTLD was the most common cancer diagnosis among the
transplant recipients, accounting for 78% of all tumor types
in this group. Among the controls, genitourinary cancer was
the most frequent tumor type (Table 2).
One recipient and one control subject had two separate
cancers diagnosed. One female liver transplant recipient had
a small B cell lymphoma at the age of 3 years, and 23 years
later, a large B cell lymphoma in the ileum, which led to her
death. In the control group, one male had a Hodgkin












Age at time of study (alive) (years) 25.8 (18.3–44.0) 26.3 (18.4–44.0) 25.7 (19.7–37.2) 24.4 (18.3–38.4) 26.4 (18.1–44.1) 0.26
Post-Tx time (years) 18.0 (0.3–30.0) 20.0 (0.7–30.0) 15.0 (0.4–27.0) 13.0 (0.3–25.0)
Males, n (%) 139 (59.7) 92 (67.2) 25 (47.2) 22 (51.2) 691 (59.7) 0.52
Age at time of Tx (years) 7.9 (0.4–15.9) 7.9 (1.1–15.9) 4.9 (0.4–15.9) 10.3 (1.0–15.9)
Malignancy, n (%) 18 (7.7) 14 (10.2) 2 (3.8) 2 (4.7) 8 (0.7) < 0.001*
Alive, n (%) 173 (74.2) 117 (85.4) 30 (56.6) 26 (60.5) 1155 (99.8) < 0.001*
Age of cancer diagnosis (years) 18.9 (3.3–33.9) 18.7 (4.1–25.6) 18.6 (3.3–33.9) 17.3 (12.2–22.3) 26.2 (13.0–29.3) 0.13
Time from Tx to cancer diagnosis (years) 12.0 (1.8–23.6) 13.3 (6.9–23.6) 10.7 (1.8–19.7) 7.9 (4.7–11.1)
Data are presented as median (range) or number of subjects (%). p value between all Tx recipients and controls. p values from the Mann-WhitneyU test




lymphoma at the age of 13 and 10 years later, a basal cell
carcinoma of the skin. Only the first malignancy of each study
subject was included to the study.
All the control subjects diagnosed with cancer were alive at
the time of the study, while in the transplant group, nine (50%)
of the 18 patients with cancer had died. Twelve percent (7/60)
of all deaths among transplant patients were due to cancer. The
highest rate of death caused by malignancy was in the KTx
group, where 25% of all deaths were cancer-related. Among
LTx and HTx recipients, the cancer-related death rate was 4
and 6 %, respectively. All but one of the deaths caused by
cancer occurred in patients with PTLD. In the transplant
group, the five-year survival after cancer diagnosis was 69%
(95% CI 0.50–0.96).
Cancer among the transplant population
The patient demographics did not differ significantly between
the transplant recipients with or without cancer diagnosis
(Table 3). The recipients with cancer diagnosis tended to be
younger at the time of transplantation than those without can-
cer diagnosis (median 5.9 IQR 1.7–10.6 vs. 8.1 IQR 2.6–
13.4 years, respectively); however, the difference did not
reach statistical significance (p = 0.192). At the time of the
study, 76% of the non-cancer transplant recipients were alive,
while only 50% of the recipients with cancer had survived
(Fig. 3). The time from cancer diagnosis to death was remark-
ably short, median 0.66 years (IQR 0.08–1.61) and 0.46 years
(IQR 0.08–0.99) in all cancer patients and in the patients with
PTLD, respectively. Among re-transplanted recipients, noma-
lignancies were reported.
The kidney transplant recipients had a higher risk for can-
cer (HR 27.7, 95% Cl 8.0-96.6) compared with controls
(Fig. 4). The vast majority of all cancers after kidney trans-
plantation (83%) were PTLDs (Table 2). Among the liver and
heart transplant recipients, the risk for cancer tended to be
increased when compared with controls (HR 5.6, 95% CI
0.9–33.6; and HR 6.4, 95% CI 0.9–45.9, respectively) (Fig.
1); additional data are given in Online Resources (ESM_2,
ESM_3). The liver transplant recipients were younger at the
time of transplantation than other recipients, and the kidney
transplant recipients had the longest follow-up time. Median
age at cancer diagnosis did not differ between the transplant
groups (Table 1). Multivariate analysis with Cox proportional-
hazards models (Table 4) showed that type of transplant (liver
HR 0.50 (95% CI 0.11–2.24), heart HR 0.63 (95% CI
Table 2 Cancer diagnoses in


















Lymphoma 15 1 12 1 1 2
NHL 12 10 2
HL 1 1 1 1
Small B cell 1 1
Unknown* 1 1
Genitouretral 1 3 1 1 2
Skin 2 1 1
Other 4 1 1 2
TOTAL 18 8 14 3 2 3 2 2
Tx transplant, KTx kidney transplant, LTx liver transplant, HTx heart transplant, NHL non-Hodgkin lymphoma,
HL Hodgkin lymphoma







































1.0 2.0 4.0 8.0 16.0 32.0 64.0
HR
Fig. 1 Difference in cancer risk between transplant recipients and controls. HR hazard ratio, 95% CI 95% confidence interval, Tx transplant
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0.14-–.87)), age at time of transplantation (5–9.99 years HR
0.94 (95% CI 0.25–3.55), over 10 years HR 0.83 (95% CI
0.27–2.55)), year of transplant (1994–2003 HR 1.27 (95%
CI 0.46–3.49), 2004–2015 HR 1.56 (95% CI 0.16–15.9)), or
sex (female HR 0.92 (95% CI 0.35–2.42)) did not influence
the cancer risk.
Eleven (61%) of all cancers among the transplant recipients
were diagnosed after their 18th birthday while the remaining
seven (39%) cancers were detected in patients under 18 years
of age. The age at the time of transplantation did not differ
significantly between the patients with cancer diagnosed be-
fore or after 18 years of age (2.4 years, IQR 1.5–8.8 vs.
8.4 years, IQR 2.3–11.3, p = 0.179) and, consequently, the
time between transplantation and cancer diagnosis was signif-
icantly shorter among the younger age group (7.1 years, IQR
4.0–10.6 vs. 15.2 years, IQR 10.5–19.7 p = 0.007). In both
age groups, PTLD was the most common cancer type, ac-
counting for 71% among patients under 18 years at time of
cancer diagnosis and 82% in the age group older than 18 years
at cancer diagnosis. Additionally, one squamous cell carcino-
ma and one small B cell lymphoma were found in the younger
age group, and one testicular teratocarcinoma and one basal
cell carcinoma of the skin in recipients older than 18 years.
PTLD, EBV serology, and type of immunosuppression
A total of 14 Tx recipients had PTLD. The median age at the
time of transplantation or the time between transplantation and
cancer diagnosis was not significantly different (p = 0.382)
between recipients with PTLD (median 4.2 (IQR 1.7–10.5)
years) and other types of cancer (median 9.7 (IQR 3.3–
13.3 years). The median time from transplantation to the can-
cer diagnosis was 12.9 (IQR 9.2–16.9) years in the PTLD
group and 7.6 (IQR 3.1–16.7) years in the patients with other
cancers (p = 0.245). Most of the recipients with cancer other
than PTLD were alive at index day (75%) while 43% of the
patients in the PTLD group were alive (p = 0.576).
In all but one patient with PTLD, EBV serology was avail-
able and positive at the time of PTLD diagnosis as a sign of
previous or current EBV infection. In the remaining case,
EBV serology was not available. Pre-transplant EBV serology
was available for seven patients and all but one had serocon-
version between transplantation and PTLD diagnosis. In ten
cases, histological examination of the tumor tissue was avail-
able. EBER in situ hybridization (ISH) was performed where
possible (n = 9) and EBER positivity was found in four cases
at the time of PTLD diagnosis. Blood EBV viral load was
available from seven patients and it varied between 8400
and 225,200 copies/mL. In two cases, the information about
immunosuppression at time of PTLD was not available.
Concerning calcineurin inhibitors, 9 patients were treated by
CsA and 3 by tacrolimus. Seven patients were on MPA, four
on AZA, and one patient receive none of these.
Table 3 Clinical characteristics
of transplant recipients with and
without cancer
With cancer n = 18 Without cancer n = 215 p value
Age at time of Tx (years) 5.9 (1.1–14.3) 8.1 (0.4–15.9) 0.192
Males, n (% within the group) 11 (61.1) 128 (59.5) 0.553
Post-Tx time (years) 18.7 (6.7–28.0) 18.0 (0.3–30.0) 0.849
Age at index day* (years) 24.3 (11.6–36.0) 24.7 (0.8–44.0) 0.469
Alive, n (% within the group) 9 (50.0) 164 (76.3) 0.023§
Age at death (years) 20.2 (11.6–25.9) 16.6 (0.8–37.5) 0.168
Data are presented as median (range) or number of subjects (%). p values from theMann-WhitneyU test and from
Fischer’s exact test, as appropriate
Tx transplantation
*Index day, day of death, or last follow-up day
§Statistically significant
Fig. 2 The cumulative cancer incidence among transplant recipients and




Cancer is a known threat after solid organ transplantation [7,
10, 19]. The increased cancer risk is mainly due to prolonged
exposure to immunosuppressive medication, and pediatric
transplant recipients are therefore considered a high-risk
group [21, 22]. The majority of previous reports describe
early-appearing cancers diagnosed shortly after pediatric
transplantation, whereas studies on adult patients with a his-
tory of pediatric solid organ transplantation are scarce [8, 13,
18]. In the present study, based on the data from the National
Population Register Center and the Finnish Cancer Registry,
we focused on adult survivors after pediatric transplantation.
In our cohort, 61% of cancers were detected after the subjects’
Fig. 3 Kaplan-Meier survival
curve for transplant recipients
with and without cancer diagnosis
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18th birthday. The novelty of this study is the long follow-up
time after pediatric solid organ transplantation.
In the present study, cancer was diagnosed in 8 % of the
solid organ transplant recipients after a median follow-up time
of 18.0 years, which is in accordance with the previous data
reported from pediatric and adult cohorts [8, 10, 23, 24].
According to Simard et al. [8], the cumulative incidence of
cancer in pediatric population is 7% with a median follow-up
time of 9.5 years, while Kitchlu et al. have recently reported a
cumulative incidence of 20% during 10.8 years’ follow-up
[10].
The vast majority of cancers in pediatric reports are diag-
nosed within the first few years after transplantation [7, 10],
which is probably due to more intensive immunosuppression
regimen and higher risk for cancers related to viral infections,
such as PTLD. Among the adult recipients, cancer incidence
increases further along the time from transplantation [24],
which is at least partly explained by the higher incidence of
cancer at older age in general. In the present study, the major-
ity of cancers were diagnosed at young adult age, and a study
by Park et al. [25] showed that highest risk for post-transplant
malignancy was among transplant age group 0–19 years.
The current study population differs from most of the pre-
vious pediatric studies because the patient selection was re-
stricted to pediatric recipients older than 18 years of age at the
time of the study, and we had three different solid organ trans-
plantation groups. This gives a novel option to show that a
significant age-dependent increase in cumulative cancer inci-
dence is detected in early adulthood in pediatric transplant
population after a median follow-up time of 18 years, and
compares kidney, liver, and heart transplant recipients’ risk
of cancer. The difference in cumulative cancer incidence and
cancer-specific mortality was significantly higher when com-
pared with matched controls, which is in accordance with the
previous registry studies by Benoni et al. [26] and Acuna [27].
However, in the present study, the cancer risk and cancer-
related mortality were lower among the liver and heart trans-
plant recipients than the kidney transplant recipients, which
was a somewhat surprising finding. Studies comparing cancer
risk in different transplant groups are scarce. In two large
registry studies, heart and liver transplant recipient’s risk for
malignancies was higher than kidney transplant recipients [7,
10]. In our study population, kidney transplant recipients had
the longest follow-up time, and the patients were younger at
the time of transplantation than heart transplant recipients.
Our findings are compatible with Serrano et al. [18] in that
the difference in cumulative cancer incidence between trans-
plant recipients and matched controls increases with longer
follow-up time and does not show a plateau during 25 years
of follow-up (Fig. 2).
In our transplant cohort, the most commonmalignancywas
PTLD (78%), which is in accordance with the previous data
showing that PTLD and lymphomas are the most frequently
found malignancies among transplant recipients [7, 10, 12,
18]. Unlike previous studies [16, 28–30], our series did not
include any early-onset PTLDs (diagnosedwithin 2 years after
transplantation). The median post-transplantation time to can-
cer diagnosis was 12.9 years among the PTLD patients and
12.0 years in patients with other types of cancers, which is
longer than in the studies by Smith and Koukourgianni, [9, 11]
but comparable with a study among young KTx recipients
where the median time to cancer was 14.7 years [31]. In a
Swedish registry study, all cancer cases except non-Hodgkin
lymphoma occurred during adulthood [8]. This confirms the
present finding that a significant number of cancers after pe-
diatric transplantation appear during adult age. PTLD recur-
rences are reportedly rare. In our cohort, only one patient with
a history of small B cell lymphoma during childhood devel-
oped non-Hodgkin lymphoma over 20 years after the primary
lymphoma diagnosis. In earlier studies, the reported PTLD
relapse rate varies between 0 and 12% [32–34]. The risk for
PTLD recurrence was found to be higher in patients on ste-
roids after PTLD diagnosis [35] and lower in patients treated
with rituximab and low-dose chemotherapy [34].
In our cohort, the incidence of solid tumors other than
PTLD and non-melanoma skin cancers was lower than those
reported in earlier studies [7–9, 13, 18]. The lower incidence
of solid tumors may be at least partly explained by population
and environmental differences in cancer risk. In the Nordic
countries, the level of ultraviolet light exposure is low, and
Table 4 Potential and known risk factors for cancer after pediatric solid
organ transplantation with univariate and multivariate Cox proportional-
hazards models
Univariate Multivariate
HR 95% CI HR 95% CI
Organ
Kidney Ref. Ref.
Liver 0.50 0.11, 2.19 0.50 0.11, 2.24
Heart 0.63 0.14, 2.79 0.63 0.14, 2.87
Tx age (years)
0–4.99 Ref. Ref.
5–9.99 0.99 0.27, 3.68 0.94 0.25, 3.55
10–15.99 0.86 0.30, 2.43 0.83 0.27, 2.55
Tx year
1982–1993 Ref. Ref.
1994–2003 1.26 0.47, 3.36 1.27 0.46, 3.49
2004–2015 1.38 0.16, 12.2 1.56 0.16, 15.9
Sex
Male Ref. Ref.
Female 0.98 0.27, 3.68 0.92 0.35, 2.42
For categorical variables, the reference category is marked with “Ref.”
HR hazard ratio, 95% CI 95% confidence interval, Tx transplant
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transplant recipients are well-informed to avoid unnecessary
exposure to sunlight and to use sun protection. In one Dutch
study, cancer incidence rate during 30-years follow-up was
relatively high, 41% [13]. Like in the report from Australia
and New Zealand, the majority of cancers were non-
melanoma skin cancers [31]. Data from a long-term follow-
up study on Nordic pediatric liver transplant patients showed
that age is a significant risk factor for cancer, and the absolute
risk for most cancers increases in patients older than 20 years
of age [36].
Furthermore, remarkably high mortality to post-
transplant malignancies has been reported by earlier studies
[18, 19, 26, 27]. Lower survival has been linked to PTLD
diagnosis and age over 18 years at the time of cancer diag-
nosis. In the present study, the percentage of the patients
who died of cancer was 12%, which is in accordance with
the study by Ploos et al. [13]. The mortality rate reported
from Minnesota was remarkable high, at 64% [18]. The
Minnesota study presented data from an earlier era, which
at least partly explains the higher mortality rate. Also in the
present study, the highest numbers of cancer-caused deaths
were among KTx recipients. LTx and HTx recipients’ can-
cer mortality was comparable and lower than KTx recipi-
ents’. In the present study, the time interval from cancer
diagnosis to death was relatively short, which supports the
previous data. This is probably caused by aggressive pro-
gression of post-transplant cancers, especially PTLD, and
increased toxicity of cancer treatments in patients with a
history of solid organ transplantation and chronic disease.
Based on these findings, careful follow-up by health care
providers and self-monitoring for cancer symptoms in
adults with a history of pediatric solid organ transplantation
is warranted.
A difference in the cancer incidence between different
graft types was observed, but was not statistically signifi-
cant. Yanik et al. [7] have recently shown in a register-based
data set consisting of more than 17,000 patients that the
incidence of malignancies is significantly increased among
pediatric solid organ transplant recipients, with the highest
incidence in small bowel recipients, followed by heart/lung,
liver, and kidney transplant patients. The vast majority of
the diagnosed malignancies were early onset non-Hodgkin
lymphomas, and the highest risk for cancer was among pa-
tients less than 12 months from transplantation. Eighteen
percent of the malignancies were diagnosed in patients aged
18 years or more. Kitchlu et al. [10] have recently shown
that pediatric liver and heart transplantation recipients have
the highest cancer incidence. In the present study, the
highest cancer incidence was among kidney transplant re-
cipients, and the difference compared with matched controls
was statistically significant only in this patient group. This
finding may be due to unequal sample sizes, longer follow-
up time in kidney transplant recipients than in other
recipients, and the overall higher early mortality among liv-
er and heart recipients than among kidney recipients.
Because this is a register-based follow-up study, our possi-
bilities to analyze risk factors affecting cancer incidence are
somewhat restricted. Surprisingly, in our cohort, the cancer
risk was not affected by the transplant era. On the contrary, a
slightly higher hazard ratio for cancer diagnosis was seen in
recipients transplanted during the twenty-first century com-
pared with those transplanted during the earlier decades.
This may be due to changes in immunosuppression protocol.
CsA- and AZA-based immunosuppression was used in the
earliest transplant cohort (1982–1993) in our study, and the
use of tacrolimus and mycophenolate has increased after that.
On the other hand, CsAwas the most-used calcineurin inhib-
itor (64%), and MPA was used in 44% of the patients with
cancer diagnosis. Another difference from the early era at our
institution is that induction therapy with basiliximab has been
used in kidney and liver transplant recipients since the year
2000.
The main weakness of the present study is the relatively
small number of study subjects. On the other hand, this is a
nationwide study with a 100 % coverage of both transplant
recipients and cancer diagnoses. The follow-up time exceeds
with that in the majority of previous studies. In addition, the
control group consists of population-based age-, gender-, and
hometown-matched subjects, which in our opinion minimizes
the regional differences in cancer incidence.
In conclusion, improved graft and patient survival after
pediatric solid organ transplantation have raised new chal-
lenges, such as long-term effects related to the primary disease
and life-long exposure to immunosuppression. It is likely that
immunosuppression increases the risk for malignancies, espe-
cially those triggered by viral infections. Recommendations
for cancer screening after solid organ transplantation have
been made [37], but the recommendations vary and have
mostly been made for kidney transplant recipients. Based on
our present findings, pediatric kidney, liver, and heart trans-
plant recipients have elevated risk for cancer morbidity, which
increases further beyond the third and fourth decades of life.
This necessitates an active, systematic, and coherent screening
schedule for surveillance.
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